© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
pan-genotype HCV NS3/4A protease inhibitor
proj. oral QD dosing, well-tolerated in rodent
deuteration reduced CYP TDI
J. Med. Chem., Nov. 23, 2020
Bristol-Myers Squibb, NJ + MA + CT + IN
Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.